NCT03951402 - Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions

Prolonged QTc IntervalPharmacokinetic

Interventions

DRUG

100 mg CG5503 (tapentadol hydrochloride) PR tablet

100 mg CG5503 (tapentadol hydrochloride) PR tablet.

DRUG

Placebo matching CG5503 PR tablet

Matching placebo tablet to CG5503 PR tablet.

DRUG

Placebo matching moxifloxacin capsule

Matching placebo capsule to moxifloxacin capsule.

DRUG

400 mg Moxifloxacin tablet (overencapsulated)

Overencapsulated 400 mg Moxifloxacin tablet.

Trial Locations (1)

DE001 - Contract research organisation, Neuss